What is Tirzepatide?
Tirzepatide (commonly known as Mounjaro under a different brand name) is a dual-action GLP-1 and GIP research peptide widely studied for its effects on appetite regulation and metabolic function.
Alluvi supplies Tirzepatide in pre-filled research pens designed for controlled R&D use. Each pen offers precision multi-dosing, stability, and ease of handling, making it suitable for structured laboratory protocols.
Pre-filled and ready to use, these pens eliminate the need for reconstitution, allowing for accurate and consistent dose measurement.
Choosing Between 20mg & 40mg Pens
The 20mg and 40mg options refer to the total amount of Tirzepatide contained in each pen. Selection depends on your total research dosing requirements.
Example:
A protocol using 2.5mg for 4 weeks and 5mg for 2 weeks equals a total of 20mg.
20mg Tirzepatide Pen
Best suited for early-stage research or gradual titration:
Designed for 2.5mg–5mg dosing protocols
Typically provides up to 8 weeks supply
40mg Tirzepatide Pen
Ideal for advanced or extended studies:
Supports 2.5mg, 5mg, 7.5mg, and 10mg dosing
Provides approximately 12–16 weeks supply, depending on protocol
Switching from Mounjaro (MJ)
For researchers already working with Mounjaro (tirzepatide), transitioning to Alluvi Tirzepatide can be done without restarting protocols. Equivalent dosing can typically be maintained without re-titration.
Why Choose Alluvi Pens?
Multi-dose precision: Easily adjust dosing using the dial mechanism
High stability: Formulated and stored to maintain compound integrity
Ease of use: Pre-filled design reduces handling and improves consistency
Pro Tip
Allow the pen to reach room temperature before use in research settings. Cold liquid may affect handling during administration procedures.
Summary
20mg Pen: Ideal for low-dose or early-stage research (2.5mg–5mg)
40mg Pen: Suitable for advanced protocols (2.5mg–10mg)
UK Supply & Ordering
Secure packaging and clear labeling
Discreet UK dispatch options
Reliable stock availability
Fast checkout and responsive support



